Publication Name	World Journal of Gastroenterology
Manuscript ID	25743
Country	China

Received	2016-03-22 09:58
Peer-Review Started	2016-03-22 16:11
To Make the First Decision	2016-04-14 10:09
Return for Revision	2016-04-14 13:58
Revised	2016-05-02 08:55
Second Decision	2016-05-11 15:56
Accepted by Journal Editor-in-Chief	2016-05-11 16:08
Accepted by Company Editor-in-Chief	2016-05-23 16:27
Articles in Press	2016-05-23 16:27
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-05-27 08:47
Publish the Manuscript Online	2016-06-13 09:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Feng Wen and Qiu Li
Funding Agency and Grant Number
Corresponding Author	Qiu Li, Professor, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. fbqiu9@163.com
Key Words	Cetuximab; Colorectal cancer; Metastatic; Toxicity; Chemotherapy
Core Tip	The advent of epidermal growth factor receptor monoclonal antibodies (EGFR mAbs), especially cetuximab, has provided a meaningful transformation in the available treatment options for advanced colorectal cancer (CRC). Nevertheless, their efficacy is accompanied by some undesired complications. Additionally, combination treatments comprising EGFR mAbs and traditional cytotoxic agents have resulted in a more complex management of CRC treatment-related side effects. Therefore, it is imperative to understand and appropriately address the treatment dilemmas of cetuximab combined with chemotherapy for the management of metastatic CRC.
Publish Date	2016-06-13 09:14
Citation	Wen F, Li Q. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol 2016; 22(23): 5332-5341
URL	http://www.wjgnet.com/1007-9327/full/v22/i23/5332.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i23.5332

Full Article (PDF)	WJG-22-5332.pdf
Full Article (Word)	WJG-22-5332.doc
Manuscript File	25743-Review.doc
Answering Reviewers	25743-Answering reviewers.pdf
Audio Core Tip	25743-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25743-Conflict-of-interest statement.pdf
Copyright License Agreement	25743-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25743-Language certificate.pdf
Peer-review Report	25743-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	25743-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	25743-Scientific misconduct check.pdf
Scientific Editor Work List	25743-Scientific editor work list.pdf